- Home
- DGICB vs FULC Comparison
DGICB vs FULC Comparison
Compare DGICB & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGICB
- FULC
- Stock Information
- Founded
- DGICB 1986
- FULC 2015
- Country
- DGICB United States
- FULC United States
- Employees
- DGICB N/A
- FULC N/A
- Industry
- DGICB Property-Casualty Insurers
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- DGICB Finance
- FULC Health Care
- Exchange
- DGICB Nasdaq
- FULC Nasdaq
- Market Cap
- DGICB 562.0M
- FULC 469.0M
- IPO Year
- DGICB N/A
- FULC 2019
- Fundamental
- Price
- DGICB $15.50
- FULC $9.36
- Analyst Decision
- DGICB
- FULC Buy
- Analyst Count
- DGICB 0
- FULC 7
- Target Price
- DGICB N/A
- FULC $9.14
- AVG Volume (30 Days)
- DGICB 940.0
- FULC 536.5K
- Earning Date
- DGICB 10-30-2025
- FULC 10-29-2025
- Dividend Yield
- DGICB 4.19%
- FULC N/A
- EPS Growth
- DGICB 965.80
- FULC N/A
- EPS
- DGICB 2.34
- FULC N/A
- Revenue
- DGICB $993,644,532.00
- FULC N/A
- Revenue This Year
- DGICB $2.26
- FULC N/A
- Revenue Next Year
- DGICB $3.46
- FULC N/A
- P/E Ratio
- DGICB $7.99
- FULC N/A
- Revenue Growth
- DGICB 3.36
- FULC 2752.05
- 52 Week Low
- DGICB $13.19
- FULC $2.32
- 52 Week High
- DGICB $20.46
- FULC $10.11
- Technical
- Relative Strength Index (RSI)
- DGICB 50.31
- FULC 54.41
- Support Level
- DGICB $15.33
- FULC $8.89
- Resistance Level
- DGICB $15.70
- FULC $10.09
- Average True Range (ATR)
- DGICB 0.27
- FULC 0.70
- MACD
- DGICB 0.10
- FULC -0.04
- Stochastic Oscillator
- DGICB 38.14
- FULC 59.44
About DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.